Sulphur Analogues of Homoisoflavonoids as Potential Treatments for Neovascular Eye Diseases
Authors:
- Jacob D. HilesJHJacob D. Hiles
- Kamakshi SishtlaKSKamakshi Sishtla
- Joseph C. BearJBJoseph C. Bear
- Jeremy K. CockcroftJCJeremy K. Cockcroft
- Elizabeth I. OparaEOElizabeth I. Opara
- Ali A. Al‐KinaniAAAli A. Al‐Kinani
- Raid G. AlanyRaid G. Alany
- Timothy W. CorsonTCTimothy W. Corson
- Sianne L. SchwikkardSSSianne L. Schwikkard
Open Access
- 31 January 2026
- journal article
- Published by Wiley in ChemMedChem
- Vol. 21 (2) , e202500824
Abstract
Treatment of neovascular eye diseases like age‐related macular degeneration require a compound that is not toxic to ocular cells, that can reduce inflammation and inhibit angiogenesis. Homoisoflavonoids, naturally occurring compounds isolated primarily from the Hyacinthaceae sub‐family of plants, have shown promise as anti‐inflammatories and inhibitors of angiogenesis. A series of sulphur analogues, (3‐benzylidene thiochroman‐4‐ones), were synthesised via a three‐step procedure. These compounds were evaluated for selectivity towards endothelial cells over non‐endothelial cells and their ability to inhibit COX‐II over COX‐I.Their potential anti‐angiogenic activity was assessed using the Matrigel tube formation assay. ( 3Z ) ‐3‐[(3‐bromophenyl)methylidene]‐6‐methoxy‐2,3‐dihydro‐4H‐1‐benzothiopyran‐4‐one ( 10 ) was most active with respect to anti‐proliferation against human retinal endothelial cells (HREC cells) (GI 50 3.07 μM). All demonstrated selectivity with all GI 50 values against retinal pigment epithelial cell line ARPE‐19 >100 µM, with the exception of ( 3Z ) ‐6‐bromo‐3‐[(4‐nitrophenyl)methylidene]‐2,3‐dihydro‐4H‐1‐benzothiopyran‐4‐one ( 12 ), which was not toxic to either. ( 3Z ) ‐3‐[(3‐bromophenyl)methylidene]‐6‐methoxy‐2,3‐dihydro‐4H‐1‐benzothiopyran‐4‐one ( 10 ) showed significant reduction in angiogenesis properties in a Matrigel‐based tube formation assay (38.79%, 5 µM, 56.41%, 10 µM). ( 3Z ) ‐6‐bromo‐3‐[(3‐bromophenyl)methylidene]‐2,3‐dihydro‐4H‐1‐benzothiopyran‐4‐one ( 7 ) was found to be the most active against COX‐II with inhibition of 22.7 % (4.35 nM). The 3‐benzylidene thiochroman‐4‐ones show promise as antiangiogenic agents, but limited selectivity to COX‐II over COX‐I.Keywords
This publication has 29 references indexed in Scilit:
- Ranibizumab Therapy for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2010
- In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extractNature Protocols, 2010
- Mediators of ocular angiogenesisJournal of Genetics, 2009
- Inhibition of choroidal neovascularization by homoisoflavanone, a new angiogenesis inhibitor2008
- Homoisoflavanone inhibits retinal neovascularization through cell cycle arrest with decrease of cdc2 expressionBiochemical and Biophysical Research Communications, 2007
- Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesionsBritish Journal of Ophthalmology, 2007
- Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapyProgress in Retinal and Eye Research, 2007
- Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapySeminars in Oncology, 2004
- Anti-Angiogenic Activity of a Homoisoflavanone fromcremastra appendiculataPlanta Medica, 2004
- The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the ratCurrent Eye Research, 1999